AbCellera Biologics Inc. Common Shares: Private Market and Dual-class Share Analysis

In the ever-evolving world of biotechnology, AbCellera Biologics Inc. has made significant strides with its innovative approach to drug discovery. This article delves into the intricacies of AbCellera's common shares, focusing on their private market status and dual-class share structure. Let's explore the key aspects that make AbCellera's shares a compelling investment opportunity.

Understanding AbCellera Biologics Inc.

AbCellera Biologics Inc. is a leading company in the field of antibody discovery. Its proprietary platform combines artificial intelligence and high-throughput technologies to rapidly identify and engineer novel antibodies. This cutting-edge approach has enabled AbCellera to partner with some of the world's largest pharmaceutical companies, including Novartis and Eli Lilly.

Private Market Status

AbCellera Biologics Inc. operates as a private company, which means its shares are not publicly traded on any stock exchange. This private market status offers several advantages:

• Strategic Flexibility: As a private company, AbCellera can focus on long-term growth and innovation without the pressure of quarterly earnings reports.
• Control and Focus: The absence of public shareholders allows the company's management team to make decisions in the best interest of the company, without the distraction of short-term market fluctuations.
• Capital Allocation: Private companies can allocate capital more efficiently, as they are not required to meet the financial obligations of public shareholders.

Dual-class Share Structure

AbCellera's dual-class share structure is another key feature that distinguishes it from traditional companies. This structure involves two classes of shares: Class A and Class B. Here's a breakdown of the differences:

• Voting Power: Class B shares have 10 times the voting power of Class A shares, giving the company's founders and early investors significant control over corporate decisions.
• Dividends: Both classes of shares receive equal dividends.
• Market Value: Class A shares are typically more liquid and have a higher market value compared to Class B shares.

Investment Opportunities

The combination of AbCellera's private market status and dual-class share structure presents several investment opportunities:

• Long-term Growth Potential: As a private company, AbCellera can focus on long-term growth without the pressure of short-term market expectations.
• Innovation and Technology: The company's cutting-edge antibody discovery platform positions it as a leader in the biotechnology industry.
• Strategic Partnerships: AbCellera's partnerships with major pharmaceutical companies provide a strong foundation for future growth.

Case Study: Novartis Collaboration

A prime example of AbCellera's success is its collaboration with Novartis. In 2018, the two companies announced a multi-year partnership to discover and develop novel antibodies for various diseases. This partnership highlights AbCellera's ability to leverage its technology and expertise to create valuable drug candidates.

In conclusion, AbCellera Biologics Inc. offers a unique investment opportunity with its private market status and dual-class share structure. As a leader in antibody discovery, the company has the potential to make significant strides in the biotechnology industry. Investors looking for long-term growth and innovation should consider AbCellera as a compelling investment option.